Telix Looks Materially Undervalued Given Pipeline -- Market Talk

Dow Jones

Apr 08, 2025

0433 GMT - Telix Pharmaceuticals' Australia-listed stock looks materially undervalued to UBS analysts given the strength of its therapeutic pipeline. They point out that the stock has been trading below what they calculate to be the combined valuation of Telix's Illuccix, Gozellix, Pixclara and Zircaix products, all of which are either approved for use in the U.S. or stand a good chance of being approved. The scientific and clinical failure that the valuation implies is highly unlikely, they write in a note to clients. With no obvious need to raise external funds and a U.S. manufacturing base, UBS keeps its buy rating and A$36.00 target price on Telix. Shares are up 7.0% at A$24.78. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 08, 2025 00:33 ET (04:33 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2525381078"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525381078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525381078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 12:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525381078","market":"fut","top_or_hot":-1,"title":"Telix Looks Materially Undervalued Given Pipeline -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0433 GMT - Telix Pharmaceuticals' Australia-listed stock looks materially undervalued to UBS analysts given the strength of its therapeutic pipeline. They point out that the stock has been trading below what they calculate to be the combined valuation of Telix's Illuccix, Gozellix, Pixclara and Zircaix products, all of which are either approved for use in the U.S. or stand a good chance of being approved. The scientific and clinical failure that the valuation implies is highly unlikely, they write in a note to clients. With no obvious need to raise external funds and a U.S. manufacturing base, UBS keeps its buy rating and A$36.00 target price on Telix. Shares are up 7.0% at A$24.78. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 08, 2025 00:33 ET (04:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Looks Materially Undervalued Given Pipeline -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Looks Materially Undervalued Given Pipeline -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-08 12:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0433 GMT - Telix Pharmaceuticals' Australia-listed stock looks materially undervalued to UBS analysts given the strength of its therapeutic pipeline. They point out that the stock has been trading below what they calculate to be the combined valuation of Telix's Illuccix, Gozellix, Pixclara and Zircaix products, all of which are either approved for use in the U.S. or stand a good chance of being approved. The scientific and clinical failure that the valuation implies is highly unlikely, they write in a note to clients. With no obvious need to raise external funds and a U.S. manufacturing base, UBS keeps its buy rating and A$36.00 target price on Telix. Shares are up 7.0% at A$24.78. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 08, 2025 00:33 ET (04:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2525381078","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525381078","pubTimestamp":1744086780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0433 GMT - Telix Pharmaceuticals' Australia-listed stock looks materially undervalued to UBS analysts given the strength of its therapeutic pipeline. They point out that the stock has been trading below what they calculate to be the combined valuation of Telix's Illuccix, Gozellix, Pixclara and Zircaix products, all of which are either approved for use in the U.S. or stand a good chance of being approved. The scientific and clinical failure that the valuation implies is highly unlikely, they write in a note to clients. With no obvious need to raise external funds and a U.S. manufacturing base, UBS keeps its buy rating and A$36.00 target price on Telix. Shares are up 7.0% at A$24.78. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7067":"生物科技"},"translate_title":"鉴于管道，Telix看起来被严重低估——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9},"content_text":"0433 GMT - Telix Pharmaceuticals' Australia-listed stock looks materially undervalued to UBS analysts given the strength of its therapeutic pipeline. They point out that the stock has been trading below what they calculate to be the combined valuation of Telix's Illuccix, Gozellix, Pixclara and Zircaix products, all of which are either approved for use in the U.S. or stand a good chance of being approved. The scientific and clinical failure that the valuation implies is highly unlikely, they write in a note to clients. With no obvious need to raise external funds and a U.S. manufacturing base, UBS keeps its buy rating and A$36.00 target price on Telix. Shares are up 7.0% at A$24.78. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 00:33 ET (04:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}